Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is in preclinical trial to treat gastric/ovarian cancer. Delta-Fly Pharma, Inc. was incorporated in 2010 and is headquartered in Tokushima, Japan.
तुलना करने के लिए मीट्रिक्स | 4598 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4598पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −3.1x | −7.1x | −0.4x | |
PEG अनुपात | −1.97 | 0.01 | 0.00 | |
क़ीमत/बुक | 19.6x | 5.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 45.7x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 74.1% | 53.5% | |
उचित मूल्य अपसाइड | अनलॉक करें | 6.6% | 9.5% | अनलॉक करें |